In addition to quantifying and categorizing funding awards, Head and colleagues have tried to map research investment to research output using bibliometrics, specifically the total number of publications related to pneumonia across the study period. Understandably, an absolute count of publications does not adequately reflect research quality. Elaborate methods for the evaluation of research quality, akin to the UK national Research Excellence Framework (REF), are currently available. However, even these sophisticated approaches have their own deficiencies (Wooding et al., 2015) . More consistent and internationally validated methods are awaited. The impact of research funding on advances in clinical practice is potentially even more difficult to measure. For instance, the absence of major differences between 2009 and 2014 in British national guideline recommendations for the management of adult community-acquired pneumonia hints at a lack of substantive advances in the related evidence base over that period (Lim et al., 2015) . Is this due simply to a deficiency in relevant research investment? It can, of course, take many years for pre-clinical research to bear fruit at the bedside. In this respect, the relative increase in translational pneumonia research observed by Head and colleagues in 2011-2013 compared to earlier years hopefully presages concrete advances in clinical management in the near future.
In the meantime, the increase in pneumonia research funding between 2011 and 2013 compared to 1997 and 2010 is not a reason for complacency. Relative to the burden of disease, funding for pneumonia research is still at a lower level compared to funding for tuberculosis and influenza. In 1898, in the 3rd edition of The Principles and Practice of Medicine, Sir William Osler wrote of lobar pneumonia that it "is the most fatal of all acute diseases.….. So fatal is it in this country, at least, that one may say that to die of pneumonia is the natural end of old people". Sir Osler was writing at a time when doctors and patients did not have the benefit of antimicrobial agents nor vaccines. His words should not be taken to engender a sense of nihilism in relation to the modern management and investigation of pneumonia. The work by Head and colleagues is valuable not simply for its description of funding already awarded, but lends direction to funders and researchers in the pursuit of further research that will contribute towards the control of this dreaded illness in persons of all ages.
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